Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus fluticasone/salmeterol in moderate to severe chronic obstructive pulmonary disease
2010-023621-37Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing QVA149 arm with Fluticasone/salmeterol arm (2 arms). Primary endpoint: Normalized FEV1 AUC0-12h at week 26. Started Jan 2011; status: completed.
02
Drugs
indacaterol + glycopyrroniumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-023621-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023621-37.